Form 4: Director Stephen Sherwin Executes NBIX Stock Sale

Neurocrine Biosciences Director Stephen Sherwin exercised stock options and sold 25,000 shares under a 10b5-1 trading plan.

Summary

• Director Stephen A. Sherwin exercised options to acquire 25,000 shares of Neurocrine Biosciences (NBIX) common stock.
• The exercise involved 15,000 shares at $53.64 and 10,000 shares at $79.79.
• Following the exercise, the director sold a total of 25,000 shares at weighted average prices ranging from $163.81 to $167.31.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard portfolio management by a director.

Positives

• The director maintains a remaining beneficial ownership of 15,860 shares of common stock.
• The transactions were conducted through a pre-established Rule 10b5-1 trading plan, indicating a systematic approach to liquidity rather than reactive selling.

Negatives

• The director reduced their direct equity stake in the company by 25,000 shares through the exercise and subsequent sale.

Risks

• The director is restricted from amending or modifying the 10b5-1 trading plan once adopted, limiting flexibility in response to market volatility.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common practice for executives and directors in the biotechnology sector to manage personal portfolios and liquidity, and does not necessarily reflect a change in sentiment regarding the company's clinical or commercial prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to avoid potential conflicts of interest or accusations of insider trading.
• The scale of the sale is consistent with typical director equity management programs for mid-to-large cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the sale was executed through a pre-planned 10b5-1 arrangement.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

NBIX, Neurocrine Biosciences, Insider Trading, Form 4, Stock Options, Director Transaction